These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
293 related articles for article (PubMed ID: 36352476)
21. Safety and Efficacy of Neoadjuvant Chemotherapy for Advanced Gastric Cancer in Elderly Patients. Mukoyama T; Kanaji S; Sawada R; Harada H; Urakawa N; Goto H; Hasegawa H; Yamashita K; Matsuda T; Oshikiri T; Kakeji Y Anticancer Res; 2023 Dec; 43(12):5649-5656. PubMed ID: 38030165 [TBL] [Abstract][Full Text] [Related]
22. EORTC-1203-GITCG - the "INNOVATION"-trial: Effect of chemotherapy alone versus chemotherapy plus trastuzumab, versus chemotherapy plus trastuzumab plus pertuzumab, in the perioperative treatment of HER2 positive, gastric and gastroesophageal junction adenocarcinoma on pathologic response rate: a randomized phase II-intergroup trial of the EORTC-Gastrointestinal Tract Cancer Group, Korean Cancer Study Group and Dutch Upper GI-Cancer group. Wagner AD; Grabsch HI; Mauer M; Marreaud S; Caballero C; Thuss-Patience P; Mueller L; Elme A; Moehler MH; Martens U; Kang YK; Rha SY; Cats A; Tokunaga M; Lordick F BMC Cancer; 2019 May; 19(1):494. PubMed ID: 31126258 [TBL] [Abstract][Full Text] [Related]
23. NeoFLOT: Multicenter phase II study of perioperative chemotherapy in resectable adenocarcinoma of the gastroesophageal junction or gastric adenocarcinoma-Very good response predominantly in patients with intestinal type tumors. Schulz C; Kullmann F; Kunzmann V; Fuchs M; Geissler M; Vehling-Kaiser U; Stauder H; Wein A; Al-Batran SE; Kubin T; Schäfer C; Stintzing S; Giessen C; Modest DP; Ridwelski K; Heinemann V Int J Cancer; 2015 Aug; 137(3):678-85. PubMed ID: 25530271 [TBL] [Abstract][Full Text] [Related]
24. Neoadjuvant chemotherapy in locally advanced gastric cancer: what to avoid. Preliminary analysis of a consecutive series of patients. Rausei S; Lianos GD; Proserpio I; Ruspi L; Galli F; Frattini F; Mangano A; Rovera F; Boni L; Roukos DH; Pinotti G; Dionigi G Tumori; 2015; 101(5):511-6. PubMed ID: 25908036 [TBL] [Abstract][Full Text] [Related]
26. Correlation of pathological complete response with survival after neoadjuvant chemotherapy in gastric or gastroesophageal junction cancer treated with radical surgery: A meta-analysis. Li Z; Shan F; Wang Y; Zhang Y; Zhang L; Li S; Jia Y; Xue K; Miao R; Li Z; Ji J PLoS One; 2018; 13(1):e0189294. PubMed ID: 29370182 [TBL] [Abstract][Full Text] [Related]
27. A network meta-analysis of the short-term efficacy of five chemotherapy regimens based on cisplatin and fluorouracil for esophagogastric junctional adenocarcinoma. Wang C; Song DJ; Xu ZL; Xie SP; Hu JH Exp Mol Med; 2017 Sep; 49(9):e383. PubMed ID: 28960212 [TBL] [Abstract][Full Text] [Related]
28. Prognostic and predictive value of mismatch repair deficiency in gastric and gastroesophageal junction adenocarcinoma patients receiving neoadjuvant or adjuvant chemotherapy. Li Z; Wang Y; Ying X; Zhang L; Gao X; Jia Y; Zhang L; Wu A; Su X; Ji J J Surg Oncol; 2021 Dec; 124(8):1356-1364. PubMed ID: 34515995 [TBL] [Abstract][Full Text] [Related]
29. [Neoadjuvant chemoradiotherapy combined with surgery versus direct surgery in the treatment of Siewert type II and III adenocarcinomas of the esophagogastric junction: long-term prognostic analysis of a prospective randomized controlled trial]. Tian Y; Wang Q; Wang J; Qiao XY; Zhang J; Lin YC; Li Y; Fan LQ; Yang PG; Zhao Q Zhonghua Wei Chang Wai Ke Za Zhi; 2021 Feb; 24(2):128-137. PubMed ID: 33508918 [No Abstract] [Full Text] [Related]
30. Adjuvant (cisplatin, etoposide, and 5-fluorouracil) chemotherapy after curative resection of gastric adenocarcinomas involving the esophagogastric junction. Ryoo BY; Kang YK; Im YH; Kim YJ; Kim BS; Kim TY; Jung SH; Park JH; Baek HJ; Kim YC; Shim YM; Kim CM; Zo JI Am J Clin Oncol; 1999 Jun; 22(3):253-7. PubMed ID: 10362331 [TBL] [Abstract][Full Text] [Related]
31. Perioperative immune checkpoint inhibitors combined with chemotherapy versus chemotherapy for locally advanced, resectable gastric or gastroesophageal junction adenocarcinoma: A systematic review and meta-analysis of randomized controlled trials. Huang D; Sun F; Ke L; Li S Int Immunopharmacol; 2024 Sep; 138():112576. PubMed ID: 38941672 [TBL] [Abstract][Full Text] [Related]
32. Early endpoints of a randomized phase II trial of preoperative chemotherapy with S-1/CDDP with or without trastuzumab followed by surgery for HER2-positive resectable gastric or esophagogastric junction adenocarcinoma with extensive lymph node metastasis: Japan Clinical Oncology Group study JCOG1301C (Trigger Study). Tokunaga M; Machida N; Mizusawa J; Ito S; Yabusaki H; Hirao M; Watanabe M; Imamura H; Kinoshita T; Yasuda T; Hihara J; Fukuda H; Yoshikawa T; Boku N; Terashima M Gastric Cancer; 2024 May; 27(3):580-589. PubMed ID: 38243037 [TBL] [Abstract][Full Text] [Related]
33. Network meta-analysis comparing neoadjuvant chemoradiation, neoadjuvant chemotherapy and upfront surgery in patients with resectable, borderline resectable, and locally advanced pancreatic ductal adenocarcinoma. Hu Q; Wang D; Chen Y; Li X; Cao P; Cao D Radiat Oncol; 2019 Jul; 14(1):120. PubMed ID: 31291998 [TBL] [Abstract][Full Text] [Related]
34. Efficacy and safety of neoadjuvant sintilimab, oxaliplatin and capecitabine in patients with locally advanced, resectable gastric or gastroesophageal junction adenocarcinoma: early results of a phase 2 study. Jiang H; Yu X; Li N; Kong M; Ma Z; Zhou D; Wang W; Wang H; Wang H; He K; Li Z; Lu Y; Zhang J; Zhao K; Zhang Y; Xu N; Li Z; Liu Y; Wang Y; Wang Y; Teng L J Immunother Cancer; 2022 Mar; 10(3):. PubMed ID: 35296556 [TBL] [Abstract][Full Text] [Related]
35. Neoadjuvant therapy in triple-negative breast cancer: A systematic review and network meta-analysis. Lin YY; Gao HF; Yang X; Zhu T; Zheng XX; Ji F; Zhang LL; Yang CQ; Yang M; Li JQ; Cheng MY; Wang K Breast; 2022 Dec; 66():126-135. PubMed ID: 36265208 [TBL] [Abstract][Full Text] [Related]
36. TOPGEAR: a randomised phase III trial of perioperative ECF chemotherapy versus preoperative chemoradiation plus perioperative ECF chemotherapy for resectable gastric cancer (an international, intergroup trial of the AGITG/TROG/EORTC/NCIC CTG). Leong T; Smithers BM; Michael M; Gebski V; Boussioutas A; Miller D; Simes J; Zalcberg J; Haustermans K; Lordick F; Schuhmacher C; Swallow C; Darling G; Wong R BMC Cancer; 2015 Jul; 15():532. PubMed ID: 26194186 [TBL] [Abstract][Full Text] [Related]
37. Safety and efficacy of tislelizumab plus chemotherapy versus chemotherapy alone as neoadjuvant treatment for patients with locally advanced gastric cancer: real-world experience with a consecutive patient cohort. Jiang Q; Liu W; Zeng X; Zhang C; Du Y; Zeng L; Yin Y; Fan J; Yang M; Tao K; Zhang P Front Immunol; 2023; 14():1122121. PubMed ID: 37215127 [TBL] [Abstract][Full Text] [Related]
38. The Efficacy and Safety of First-line Chemotherapy in Advanced Esophagogastric Cancer: A Network Meta-analysis. Ter Veer E; Haj Mohammad N; van Valkenhoef G; Ngai LL; Mali RMA; Anderegg MC; van Oijen MGH; van Laarhoven HWM J Natl Cancer Inst; 2016 Oct; 108(10):. PubMed ID: 27576566 [TBL] [Abstract][Full Text] [Related]
39. Comparison of Platinum/S-1 and Platinum/5-Fluorouracil as First-Line Chemotherapy for Advanced Gastric or Gastroesophageal Junction Cancer: A Meta-Analysis Based on Randomized Controlled Trials. Luo D; Wang L; Chen X; Xiong Y; Yi F; Ding J; Ding H; Wei Y; Zhang W Chemotherapy; 2020; 65(1-2):11-20. PubMed ID: 32535588 [TBL] [Abstract][Full Text] [Related]